JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer

  • 0Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China. ydenny@126.com.
European Review for Medical and Pharmacological Sciences +

|

December 3, 2024

|

December 3, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The MKNK2 gene is abnormally expressed in many cancers, correlating with poor prognosis and altered tumor microenvironments. This suggests MKNK2 could be a biomarker for cancer progression and immunotherapy strategies.

Area Of Science

  • Oncology
  • Genomics
  • Immunology

Background

  • The role of MKNK2 in pan-cancer is not fully understood.
  • Investigating MKNK2's impact on tumor progression and the immune microenvironment is crucial.

Purpose Of The Study

  • To explore MKNK2 gene expression across various cancers.
  • To determine the prognostic value of MKNK2.
  • To assess MKNK2's association with the tumor immune microenvironment and stemness.

Main Methods

  • Utilized TCGA, GTEx, and CCLE databases for clinical and mutational data.
  • Employed bioinformatic analyses to link MKNK2 to prognosis, immune infiltration, and stemness.
  • Applied statistical software (R, SPSS) and algorithms (TIMER, CIBERSORT, EPIC).

Main Results

  • MKNK2 exhibits abnormal expression in pan-cancer, linked to poor prognosis.
  • MKNK2 levels correlate with immune cell infiltration and tumor stemness.
  • Significant associations found between MKNK2 expression, clinical outcomes, and immune markers in specific cancers like GBMLGG.

Conclusions

  • Abnormal MKNK2 expression is tied to tumor progression, immune evasion, and stemness.
  • MKNK2 shows potential as a prognostic biomarker, particularly in glioblastoma multiforme low-grade gliomas (GBMLGG).
  • Targeting MKNK2 may offer novel therapeutic strategies to improve immunotherapy efficacy.